Literature DB >> 6411337

Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.

G A van Hazel, M Scott, J Rubin, C G Moertel, R T Eagan, M J O'Connell, J S Kovach.   

Abstract

We have characterized plasma pharmacokinetics in 30 patients receiving mitomycin C (mitomycin) in doses ranging from 6 to 20 mg/m2 by iv bolus injection, either alone or in combination with other chemotherapeutic drugs. Plasma elimination of the drug was described by a two-compartment model in all but three cases, giving mean values for alpha-half-life of 8.2 mins, beta-half-life of 51.8 mins, and total body clearance of 332.9 ml/min/m2. The mean urinary excretion was 8.1% of the total dose administered. We did not detect alterations in pharmacologic parameters related to liver dysfunction, dose of mitomycin, and concomitant administration of other cytotoxic drugs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6411337

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  12 in total

1.  The difference in pharmacokinetics of mitomycin C, given either as a single agent or as a part of combination chemotherapy.

Authors:  J Verweij; M Stuurman; J de Vries; H M Pinedo
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

Review 2.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Role of hydrogen peroxide and hydroxyl radical formation in the killing of Ehrlich tumor cells by anticancer quinones.

Authors:  J H Doroshow
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

4.  Intraperitoneal hyperthermic chemotherapy: experience at Baylor University Medical Center.

Authors:  Joseph A Kuhn; James M McLoughlin; Daniel C Harris; Loraye J Talaasen; Steven W Sutton; Todd M McCarty
Journal:  Proc (Bayl Univ Med Cent)       Date:  2002-10

Review 5.  Clinical pharmacokinetics of drugs used in the treatment of breast cancer.

Authors:  V J Wiebe; C C Benz; M W DeGregorio
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

6.  Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study.

Authors:  T Fujimura; Y Yonemura; K Muraoka; H Takamura; Y Hirono; H Sahara; I Ninomiya; H Matsumoto; K Tsugawa; G Nishimura
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

7.  Pharmacokinetics of BW12C and mitomycin C, given in combination in a phase 1 study in patients with advanced gastrointestinal cancer.

Authors:  I F Dennis; J R Ramsay; P Workman; N M Bleehen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism.

Authors:  S Kerpel-Fronius; J Verwey; M Stuurman; B Kanyár; P Lelieveld; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Cardiotoxicity of mitomycin A, mitomycin C, and seven N7 analogs in vitro.

Authors:  R T Dorr; N G Shipp; J D Liddil; B S Iyengar; K R Kunz; W A Remers
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 10.  Intravesical suramin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder.

Authors:  M M Walther; W D Figg; W M Linehan
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.